| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Sep, 2024 | Jun, 2024 |
| Sales | 5,318,000 | 5,255,000 | 5,280,000 | 5,418,000 | 5,266,000 |
| Sales Growth | +1.20% | -0.47% | -2.55% | +2.89% | -1.61% |
| Net Income | 902,000 | 652,000 | 735,000 | 667,000 | 809,000 |
| Net Income Growth | +38.34% | -11.29% | +10.19% | -17.55% | +33.28% |
Merck Kgaa
(MRK.D.DX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
Fiscal Year End Date: 12/31